The cytoprotective NRF2 Pathway in Cancer Resistance and Lung
Our lab has a long-standing goal ... With Dr. Biswal, the lab has produced ... analysis to gene expression data from COPD patients at each GOLD stage of COPD.
The cytoprotective NRF2 Pathway in Cancer Resistance and Lung Disorders. Chronic Obstructive Pulmonary Disorder (COPD) is characterized by progressive deterioration of the lining of the lung. The major risk factor for COPD is smoking, influenced by additional factors. Recently a genetic analysis indicated that COPD risk was associated with variants in the NFE2L2 gene (commonly called NRF2). The NRF2 gene encodes a DNA-binding transcription factor known for its central role in regulating protective gene expression in response to chemical stress. Other cellular proteins systematically destroy the NRF2 protein, which is present in all cells. When toxic chemicals enter a cell, the NRF2 protein is stabilized and acts to turn on hundreds of genes that deactivate and remove toxins. Dietary studies have linked NRF2 to the protective actions of molecules found in broccoli sprouts and green tea. To better understand the role of NRF2 might be helpful in order to prevent and protect again COPD. The Wasserman and Sandford laboratories have been independently collaborating with Shyam Biswal (Johns Hopkins University) on NRF2 studies. Our lab has a long-standing goal of understanding how NRF2 recognizes target sequences in DNA. Building bioinformatics methods, the group attempts to predict the cis-regulatory elements in genes that will be functionally bound by the trans-activating NRF2 protein. With Dr. Biswal, the lab has produced the first chromatin immunoprecipitation experiment coupled to massively parallel sequencing. We will reveal the set of protective genes that respond to NRF2 under diverse conditions and across tissues. We will explore the mechanisms by which NRF2 acts by developing accurate models for the prediction of NRF2 binding sites and by coupling the analysis to gene expression data from COPD patients at each GOLD stage of COPD progression to determine those genes, which change in expression. The firsts results reveal 1256 target sequences bound by NRF2, many of which are present in or adjacent to genes observed to respond to NRF2. The Sandford laboratory has been working with the Biswal group to identify genetic sequence variations in the NRF2 gene that are associated with COPD susceptibility. A promising variant in the regulatory sequences of the NRF2 gene has emerged and is being examined in a secondary cohort of COPD patient samples. Understanding this network of protection will immediate relevance to ongoing projects across the CIHR, including pharmacogenomics, cancer and respiratory research. Recent advances indicate that NRF2 depends on an as yet unidentified partner protein, which this project will attempt to reveal.
3 nov. 2016 - voix au chapitre aux patients, Cancer pulmonaire Canada ..... voie; elle recevait la meilleure chimiothérapie ..... leur mère à supporter les effets.
pathologic characteristics. Neither age nor sex was correlated with the presence of p53-Abs. Most patients presented in advanced stage, comprising 28 patients.
19 oct. 2013 - 1- Chemistry of Isotopes/ Chimie des isotopes ( FLT, F-18, FDG) .... nucléaire dans l'élaboration du plan thérapeutique du cancer pulmonaire?
high-risk of developing this cancer in order (i) to determine .... ities to differentiate were tested using a cross-validation class ... Immunoassay Quantification.
Oct 19, 2007 - Speer BS & Salyers AA (1989) Novel aerobic tetracycline resistance ... Taylor DE, Jerome LJ, Grewal J & Chang N (1995) Tet(O), a protein that ...
www.effectivehealthcare.ahrq.gov to see draft research questions and reports or to join an e-mail ...... This histologic subset of lung cancer is primarily seen.
between male and female never-smokers. We concluded that the previously noted G:C to T:A transversions were mainly due to female smokers having a high ...
19 only after the pathological examination of a surgi- cal specimen. The control group included 41 patients with non-malignant disorders (20 males and 21 fe-.
Feb 17, 2006 - possesses an intrinsic carbapenem-hydrolysing oxacillinase, the expression of which ..... the sensor kinase â response regulator members of.
Feb 17, 2006 - its genetic and biochemical characterisation, and shares 56% .... natural reservoir in Shewanella oneidensis [50]. In-silico analyses of GenBank ...
Jan 6, 2009 - Images play an important role for confirming the diagnosis and patients may ..... Asingle is defined as the classification accuracy with SVMs (see ..... J. Ganesh Raghu, J. P. Lynch III, T. V. Colby, W. D. Travis, B. H. Gross, E. A..
carcinogenic process of the breast. FREQUENCY OF MUTATIONS ..... TP53 mutation in plasma strongly correlated with ..... Associations between common poly-.
of death from gynecological cancer in the western world. ... stimulation of ovarian epithelial cells [Risch, 1998] ... as epithelial, germ cell, or stromal in origin. The.
Haemin and haemoglobin do not have the same fate in the .... Regester,G.O.,. Le .... hemoglobin and hemin in chick, rat, cat, and dog: a comparative study. Nutr.
Canadians born female and 44% of Canadians born male will have cancer at some point in their life. Trans Care. Medical issues. Trans people and cancer ...Missing: